Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH
Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH
复制标题
DOI：
10.1182/blood-2010-05-285452
复制
发表时间：
2010-11-25
期刊：
影响因子：
20.3
通讯作者：
Cohen, Jeffrey I.
中科院分区：
文献类型：
--
作者：
Calattini, Sara;Sereti, Irini;Cohen, Jeffrey I.
EB 病毒 (EBV) 存在于健康人血液中的 B 细胞中；很少有研究在淋巴增殖性疾病患者血液中的其他细胞类型中寻找 EBV。我们使用一种结合免疫荧光细胞表面染色和荧光原位杂交的新技术来量化高 EBV DNA 载量患者血液中的 EBV 拷贝数和细胞类型。除CD20(+) B细胞外，EBV还存在于50%患者血液中的浆母细胞/浆细胞中，一小部分患者的单核细胞或T细胞中，以及69%的患者的“非B、非T、非单核细胞”中。 B 细胞中的平均 EBV 拷贝数显着高于浆母细胞/浆细胞。 EBV 载量与每个细胞的病毒拷贝数之间没有相关性。尽管我们在 EBV 感染的 B 细胞上检测到了 CD21（EBV B 细胞受体），但我们无法在病毒感染的 T 细胞上检测到它。这些发现扩大了血液中感染细胞类型的范围。确定高 EBV 载量患者中每个细胞的 EBV 基因组数量和感染细胞的类型可能为 EBV 淋巴增殖性疾病的发展提供额外的预后信息。 （血。2010；116（22）：4546-4559）
Epstein-Barr virus (EBV) is present in B cells in the blood of healthy people; few studies have looked for EBV in other cell types in blood from patients with lymphoproliferative disorders. We use a new technique combining immunofluorescent cell-surface staining and fluorescent in situ hybridization to quantify both EBV copy number per cell and cell types in blood from patients with high EBV DNA loads. In addition to CD20(+) B cells, EBV was present in plasmablast/plasma cells in the blood of 50% of patients, in monocytes or T cells in a small proportion of patients, and in "non-B, non-T, non-monocytes" in 69% of patients. The mean EBV copy number in B cells was significantly higher than in plasmablast/plasma cells. There was no correlation between EBV load and virus copy number per cell. Although we detected CD21, the EBV B-cell receptor, on EBV-infected B cells, we could not detect it on virus-infected T cells. These findings expand the range of cell types infected in the blood. Determining the number of EBV genomes per cell and the type of cells infected in patients with high EBV loads may provide additional prognostic information for the development of EBV lymphoproliferative diseases. (Blood. 2010; 116(22): 4546-4559)